

<b>Notice of References Cited</b>	Application/Control No. 09/765,491	Applicant(s)/Patent Under Reexamination ARBISER, JACK L.	
	Examiner Jennifer Kim	Art Unit 1617	Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-5,268,384	12-1993	Galardy, Richard E.	514/419
*	B	US-5,422,363	06-1995	Yanai et al.	514/410
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Eckhardt et al. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Annals of Oncology 7: pages 491-196, 1996.
	V	Dezube et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a Phase I AIDS clinical Trial Group study. Journal of Clinical Oncology, Vol. 16, No. 4 April, 1998 pages 1444-1449.
	W	Dorland's Illustrated Medical Dictionary, 28 <sup>th</sup> Edition, 1994 page 1004.
	X	Singh et al. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Letters, 1996, Vol. 107 No. 1, pages 109-115. ISSN:0304-3835, abstract

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

1/20/07